Derma Sciences Enrolls First Patient In DSC127 Phase II Study

Derma Sciences, Inc. (OTC Bulletin Board: DSCI) announced the first study patient has been entered into the company’s Phase II study of its drug candidate, DSC127. Enrollment of the 75-patient study, looking into the drug’s ability to accelerate healing in diabetic foot ulcers, is expected to be completed within 12 months.

More: continued here

Filed under: Dermatology on November 7th, 2008